A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes.
Delivery device
Extraperitoneal
Hepatic first pass
Insulin
Type 1 diabetes
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 04 2020
10 04 2020
Historique:
received:
11
06
2019
revised:
23
01
2020
accepted:
29
01
2020
pubmed:
6
2
2020
medline:
22
6
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Intraperitoneal insulin delivery has higher benefits than subcutaneous insulin administration but has limitations, including obstruction of the catheter used in delivery devices. To overcome these limitations this study assessed safety and efficacy of an alternative approach involving a new delivery device, named ExOlin®
Identifiants
pubmed: 32014565
pii: S0168-3659(20)30075-4
doi: 10.1016/j.jconrel.2020.01.055
pii:
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
431-441Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.